STOCKS TELEGRAPH

Tag: NDRA

  • Endra Life Sciences Inc. (NDRA) Continues its Bullish Roll After Hours. Here’s why?

    Endra Life Sciences Inc. (NDRA) Continues its Bullish Roll After Hours. Here’s why?

    Penny stock Endra Life Sciences Inc. (NDRA) has been bullish since the company announced certain quality certifications on March 31 after its earnings release on March 30. The bullish momentum of the stock started escalating on April 7 while there has been no other news. Registering a gain of 10.46% during regular trading, NDRA went on to add a further 29.59% after hours. Thus, the stock was trading at a value of $0.5790 in the late trading session on Thursday.

    NDRA’s Latest News

    Source: ISO Certification

    On March 31, the company announced it has achieved key quality management system recertification from the British Standards Institution (BSI). The recertification includes ISO 13485:2016 and EN ISO 13485:2016 under Certificate Number MD 697226 from BSI. The internationally recognized certification validates the standard and sustainability of NDRA’s Quality Management System (QMS).

    Additionally, the prior Q4 2021 results showed a reduction in the company’s net loss while the cash balance at the end of the quarter was $9.5 million.

    Could Market Happenings be the Reason?

    Since the official news are almost a week old and NDRA stock saw a sudden surge on Thursday, external factors could be at play. There have been many developments taking place in the market.

    Recently, the stock market took a hit after remarks from monetary policymakers were released. The Federal Reserve is eyeing an aggressive rise in interest rates in order to curb the hiking inflation. Moreover, the U.S. also slapped another round of sanctions on the Kremlin in response to Russia’s continued invasion of Ukraine. Thus, some expect a possible recession at the end of next year as the Fed continues hiking rates against high prices.

    While this situation led most indices on a downtrend in recent days, a bounce-back was seen on Thursday. Investors continue to mull the hawkish readout of minutes from the FED while many say a recession is highly unlikely. Economists deem next year’s recession to be way out of consensus. They suspect a period of slowdown on Wall Street but no period of negative growth in the near term.

    Conclusion

    With many negative developments taking place in the market, indices have been down recently. Being a healthcare sector, specifically diagnostic company, NDRA stock was not much bothered by the market situation as it continued slow rise over the whole week. On Thursday, however, the stock surged up big time. And since there is no official word, the stock seems to be enjoying the rebound in the indices seen on Thursday.

  • ENDRA Life Sciences Inc. (NDRA) Down After Hours on TAEUS® Regulatory Strategy Update

    ENDRA Life Sciences Inc. (NDRA) Down After Hours on TAEUS® Regulatory Strategy Update

    On February 09, ENDRA Life Sciences Inc. (NDRA) announced U.S. regulatory strategy update for its TAEUS® System. Consequently, the stock suffered a hit in the after-hours on Wednesday.

    During the regular trading session, the stock remained in the green with a gain of 4.56%. NDRA closed the regular session at $0.5600 with over 738.6K shares exchanging. Following the announcement, the stock plunged down to $0.4031 per share in the after hours. Thus, NDRA lost a huge 28.02% after the strategy update was announced in the after hours.

    The medical imaging technology developer, ENDRA Life Sciences Inc. was founded in 2007. Currently, the company has a market capitalization of $22.58 million. Its 42.17 million outstanding shares presently stand at a year-to-date loss of 19.05%. NDRA stock subtracted a value of 75.97% last year.

    ENDRA’s TAEUS® Update

    On Wednesday, the company announced a regulatory strategy change in the U.S. for its Thermo Acoustic Enhanced UltraSound (TAEUS®). NDRA has decided to opt for the De Novo pathway for the TAEUS system, building on the content of the completed 510(K) application.

    After extensive discussion with the U.S. FDA, the company had decided on De Novo as the better path forward for TAEUS market claims in the U.S. According to the company, the remaining efforts in the 510(k) would be equivalent to all for the De Novo pathway. Furthermore, NDRA believes the De Novo pathway will lead to a better market position and competitive advantage for the TAEUS system. Thus, the company is planning to withdraw its 510(k) application and pursue the De Novo pathway.

    Expansion into China

    On January 24, the company announced its expansion into China through a partnership with Shanghai General Hospital. NDRA received Institutional Review Board approval from the hospital for its first clinical study of the TEAUS device. The clinical study will evaluate TAEUS for Non-Alcoholic Fatty Liver Disease (NAFLD) in the market. This marks the first clinical research partnership of the company in Asia and eighth worldwide.

    Additionally, the study is expected to commence in 2022.

    NDRA: Financials

    On November 15, the company declared its financial results for the third quarter of 2021.

    In Q3 2021, the company suffered a net loss of $2.7 million, against $3.3 million in the prior-year period. Resultantly, the net loss per diluted share was $0.06 and $0.15 in Q3 2021 and 2020 respectively.

    Furthermore, NDRA ended the quarter with cash and cash equivalents of $11.8 million.